Top Lung Cancer News of 2017

The median OS was 18.5 months in those who received 6 or more cycles of induction chemotherapy vs 13.1 months in those who did not.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Neoadjuvant alectinib met the primary end point with a major pathologic response rate of 42% in patients with potentially resectable stage III NSCLC.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

A systematic review shows that patients with mesothelioma who received HITOCH experienced between 13 to 35 months of survival.

Study data show a small number of individuals with a lung cancer diagnosis within 12 months of a negative baseline screening result.